X
  • About
  • Advertise
  • Contact
  • Expert Resources
Get the latest news! Subscribe to the Money Management bulletin
  • News
    • Accounting
    • Financial Planning
    • Funds Management
    • Life/Risk
    • People & Products
    • Policy & Regulation
    • Property
    • SMSF
    • Superannuation
    • Tech
  • Investment
    • Australian Equities
    • Global Equities
    • Managed Accounts
    • Fixed Income
    • ETFs
  • Features
    • Editorial
    • Expert Analysis
    • Guides
    • Outsider
    • Rate The Raters
    • Top 100
  • Media
    • Events
    • Podcast
    • Webcasts
  • Promoted Content
  • Investment Centre
No Results
View All Results
  • News
    • Accounting
    • Financial Planning
    • Funds Management
    • Life/Risk
    • People & Products
    • Policy & Regulation
    • Property
    • SMSF
    • Superannuation
    • Tech
  • Investment
    • Australian Equities
    • Global Equities
    • Managed Accounts
    • Fixed Income
    • ETFs
  • Features
    • Editorial
    • Expert Analysis
    • Guides
    • Outsider
    • Rate The Raters
    • Top 100
  • Media
    • Events
    • Podcast
    • Webcasts
  • Promoted Content
  • Investment Centre
No Results
View All Results
No Results
View All Results
Home Features Outsider

From the folks who brought you Viagra – a vaccine

Outsider regrets to say that his extensive portfolio of investments does not include pharmaceutical giant Pfizer which at the time of writing has announced that with its German partner, BioNTech has come up with a COVID-19 vaccine which appears to be 90% effective.

by Outsider
November 13, 2020
in Features, Outsider
Reading Time: 1 min read
Share on FacebookShare on Twitter

Outsider’s regret is that he was not able to surf the 15% surge in in Pfizer’s share price generated by the vaccine announcement because, as everyone knows, it is handy if you can sell down a few shares during a spike.

For the record, this is not the first time that Outsider has missed the boat on a Pfizer breakthrough. The last time was in 1989 when he somehow failed to notice that the pharmaceutical giant had somehow managed, by accident, to invent Viagra.

X

Now, if Pfizer is on the money with this COVID-19 vaccine then it will be distributed to millions around the globe, which will be similar to the distribution of Viagra which apparently generated the writing of more than two million prescriptions in the US last year albeit the outcomes will be distinctly different.

From what Outsider is told, the COVID-19 vaccine will drive temperatures down while, from what he hears, Viagra tends to drive temperatures up.

Either way, Pfizer investors can stand tall, having found themselves in a happily solid position.

Tags: Covid-19OutsiderPfizerVaccine

Related Posts

Relative Return Insider: MYEFO, US data and a 2025 wrap up

by Laura Dew
December 18, 2025

In this final episode of Relative Return Insider for 2025, host Keith Ford and AMP chief economist Shane Oliver wrap...

Relative Return Insider: RBA holds, Fed cuts and Santa’s set to rally

by Staff
December 11, 2025

In this episode of Relative Return Insider, host Keith Ford and AMP chief economist Shane Oliver unpack the RBA’s decision...

Relative Return Insider: GDP rebounds and housing squeeze getting worse

by Staff Writer
December 5, 2025

In this episode of Relative Return Insider, host Keith Ford and AMP chief economist Shane Oliver discuss the September quarter...

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

VIEW ALL
Promoted Content

Consistency is the most underrated investment strategy.

In financial markets, excitement drives headlines. Equity markets rise, fall, and recover — creating stories that capture attention. Yet sustainable...

by Industry Expert
November 5, 2025
Promoted Content

Jonathan Belz – Redefining APAC Access to US Private Assets

Winner of Executive of the Year – Funds Management 2025After years at Goldman Sachs and Credit Suisse, Jonathan Belz founded...

by Staff Writer
September 11, 2025
Promoted Content

Real-Time Settlement Efficiency in Modern Crypto Wealth Management

Cryptocurrency liquidity has become a cornerstone of sophisticated wealth management strategies, with real-time settlement capabilities revolutionizing traditional investment approaches. The...

by PartnerArticle
September 4, 2025
Editorial

Relative Return: How fixed income got its defensiveness back

In this episode of Relative Return, host Laura Dew chats with Roy Keenan, co-head of fixed income at Yarra Capital...

by Laura Dew
September 4, 2025

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Podcasts

Relative Return Insider: MYEFO, US data and a 2025 wrap up

December 18, 2025

Relative Return Insider: RBA holds, Fed cuts and Santa’s set to rally

December 11, 2025

Relative Return Insider: GDP rebounds and housing squeeze getting worse

December 5, 2025

Relative Return Insider: US shares rebound, CPI spikes and super investment

November 28, 2025

Relative Return Insider: Economic shifts, political crossroads, and the digital future

November 14, 2025

Relative Return: Helping Australians retire with confidence

November 11, 2025

Top Performing Funds

FIXED INT - AUSTRALIA/GLOBAL BOND
Fund name
3 y p.a(%)
1
DomaCom DFS Mortgage
211.38
2
Loftus Peak Global Disruption Fund Hedged
110.90
3
SGH Income Trust Dis AUD
80.01
4
Global X 21Shares Bitcoin ETF
76.11
5
Smarter Money Long-Short Credit Investor USD
67.63
Money Management provides accurate, informative and insightful editorial coverage of the Australian financial services market, with topics including taxation, managed funds, property investments, shares, risk insurance, master trusts, superannuation, margin lending, financial planning, portfolio construction, and investment strategies.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Us

  • About
  • Advertise
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Financial Planning
  • Funds Management
  • Investment Insights
  • ETFs
  • People & Products
  • Policy & Regulation
  • Superannuation

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
  • News
    • All News
    • Accounting
    • Financial Planning
    • Funds Management
    • Life/Risk
    • People & Products
    • Policy & Regulation
    • Property
    • SMSF
    • Superannuation
    • Tech
  • Investment
    • All Investment
    • Australian Equities
    • ETFs
    • Fixed Income
    • Global Equities
    • Managed Accounts
  • Features
    • All Features
    • Editorial
    • Expert Analysis
    • Guides
    • Outsider
    • Rate The Raters
    • Top 100
  • Media
    • Events
    • Podcast
    • Webcasts
  • Promoted Content
  • Investment Centre
  • Expert Resources
  • About
  • Advertise
  • Contact Us

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited